Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
Pancreatic Cancer
DRUG: CCX872-B
progression-free survival, 24 weeks|subject incidence of Grade 3 or 4 adverse events, 24 weeks
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.